Real-time Estimate
Cboe BZX
12:21:39 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
330
USD
|
-0.05%
|
|
-0.12%
|
+73.16%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,350
|
3,553
|
6,296
|
7,431
|
7,031
|
12,394
|
-
|
-
|
Enterprise Value (EV)
1 |
1,168
|
3,368
|
6,112
|
7,151
|
6,772
|
11,885
|
11,577
|
11,192
|
P/E ratio
|
-20.5
x
|
-52.1
x
|
-686
x
|
36.1
x
|
49.5
x
|
63.2
x
|
53.7
x
|
44.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
31.4
x
|
52.4
x
|
26.5
x
|
15.2
x
|
9.63
x
|
13.3
x
|
10.9
x
|
9.13
x
|
EV / Revenue
|
27.2
x
|
49.7
x
|
25.8
x
|
14.6
x
|
9.27
x
|
12.7
x
|
10.2
x
|
8.25
x
|
EV / EBITDA
|
-24.9
x
|
-63
x
|
204
x
|
41.1
x
|
27.9
x
|
37.9
x
|
32.9
x
|
26.1
x
|
EV / FCF
|
-
|
-
|
2,353
x
|
-
|
40.9
x
|
28.5
x
|
48.4
x
|
35.2
x
|
FCF Yield
|
-
|
-
|
0.04%
|
-
|
2.44%
|
3.51%
|
2.07%
|
2.84%
|
Price to Book
|
7.17
x
|
15.9
x
|
25.9
x
|
14.6
x
|
10.5
x
|
13.1
x
|
9.68
x
|
7.63
x
|
Nbr of stocks (in thousands)
|
30,738
|
34,260
|
35,304
|
36,142
|
36,897
|
37,544
|
-
|
-
|
Reference price
2 |
43.92
|
103.7
|
178.3
|
205.6
|
190.6
|
330.1
|
330.1
|
330.1
|
Announcement Date
|
2/13/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
42.93
|
67.79
|
237.1
|
489.7
|
730.2
|
932.7
|
1,136
|
1,357
|
EBITDA
1 |
-46.86
|
-53.45
|
29.96
|
173.9
|
242.7
|
313.8
|
351.4
|
428.1
|
EBIT
1 |
-51.84
|
-65.66
|
-0.871
|
124.1
|
159.1
|
209.4
|
290
|
374.8
|
Operating Margin
|
-120.76%
|
-96.86%
|
-0.37%
|
25.35%
|
21.79%
|
22.45%
|
25.54%
|
27.62%
|
Earnings before Tax (EBT)
1 |
-51.05
|
-65.62
|
-8.835
|
120.8
|
174.3
|
244
|
308
|
383.9
|
Net income
1 |
-51.11
|
-65.7
|
-9.136
|
216
|
147.3
|
202.5
|
242.2
|
298.5
|
Net margin
|
-119.06%
|
-96.92%
|
-3.85%
|
44.1%
|
20.17%
|
21.72%
|
21.33%
|
22%
|
EPS
2 |
-2.140
|
-1.990
|
-0.2600
|
5.700
|
3.850
|
5.222
|
6.148
|
7.373
|
Free Cash Flow
1 |
-
|
-
|
2.597
|
-
|
165.5
|
416.9
|
239.3
|
318
|
FCF margin
|
-
|
-
|
1.1%
|
-
|
22.66%
|
44.7%
|
21.07%
|
23.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
8.67%
|
-
|
68.18%
|
132.88%
|
68.09%
|
74.29%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
112.34%
|
205.84%
|
98.79%
|
106.52%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
84.18
|
93.63
|
120.7
|
131.3
|
144
|
161.1
|
180.2
|
186
|
203
|
218.8
|
227.8
|
231.6
|
254
|
257.7
|
279.5
|
EBITDA
1 |
23.08
|
25.84
|
41.69
|
49.75
|
56.6
|
57.49
|
50.91
|
65.04
|
68.17
|
68.45
|
74.8
|
80.75
|
89.95
|
77
|
85.46
|
EBIT
1 |
13.98
|
15.37
|
29.58
|
36.76
|
42.42
|
39.81
|
32.37
|
43.62
|
43.28
|
42.41
|
50.6
|
53.41
|
64.46
|
58.38
|
68.63
|
Operating Margin
|
16.61%
|
16.42%
|
24.49%
|
27.99%
|
29.46%
|
24.72%
|
17.97%
|
23.45%
|
21.32%
|
19.38%
|
22.21%
|
23.05%
|
25.38%
|
22.65%
|
24.55%
|
Earnings before Tax (EBT)
1 |
13.05
|
14.72
|
26.34
|
35.12
|
44.65
|
40.74
|
33
|
45.08
|
55.46
|
50
|
59.05
|
61.34
|
73.62
|
65.33
|
75.13
|
Net income
1 |
12.94
|
14.52
|
25.56
|
35
|
140.9
|
39.12
|
28.86
|
34.99
|
44.3
|
55.35
|
44.8
|
46.58
|
55.77
|
54.56
|
60.74
|
Net margin
|
15.37%
|
15.51%
|
21.17%
|
26.65%
|
97.84%
|
24.29%
|
16.02%
|
18.81%
|
21.83%
|
25.29%
|
19.67%
|
20.11%
|
21.96%
|
21.17%
|
21.73%
|
EPS
2 |
0.3400
|
0.3900
|
0.6800
|
0.9200
|
3.710
|
1.030
|
0.7600
|
0.9200
|
1.160
|
1.440
|
1.153
|
1.221
|
1.454
|
1.409
|
1.558
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
5/9/22
|
8/8/22
|
11/7/22
|
2/16/23
|
5/8/23
|
8/7/23
|
11/6/23
|
2/15/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
182
|
186
|
184
|
280
|
259
|
509
|
817
|
1,202
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
2.6
|
-
|
165
|
417
|
239
|
318
|
ROE (net income / shareholders' equity)
|
-146%
|
-31.4%
|
-3.91%
|
57.4%
|
25%
|
22.6%
|
21.4%
|
19.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
43.6%
|
13.3%
|
9.17%
|
10.1%
|
10.5%
|
Assets
1 |
-
|
-
|
-
|
495.9
|
1,106
|
2,208
|
2,394
|
2,850
|
Book Value Per Share
2 |
6.130
|
6.530
|
6.890
|
14.10
|
18.10
|
25.20
|
34.10
|
43.30
|
Cash Flow per Share
2 |
-2.010
|
-2.150
|
-
|
3.110
|
5.130
|
5.480
|
1.120
|
6.450
|
Capex
1 |
-
|
-
|
-
|
25.1
|
30.6
|
38.4
|
45.3
|
47.5
|
Capex / Sales
|
-
|
-
|
-
|
5.13%
|
4.19%
|
4.12%
|
3.99%
|
3.5%
|
Announcement Date
|
2/13/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
330.1
USD Average target price
326.1
USD Spread / Average Target -1.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +73.16% | 12.39B | | -20.16% | 7.89B | | +8.01% | 6.59B | | +12.49% | 5.43B | | +40.80% | 4.96B | | -17.45% | 4.72B | | -18.76% | 4.02B | | -29.00% | 2.66B | | +63.30% | 2.37B | | -2.10% | 1.96B |
Medical Equipment
|